OTA-BA-532
GPO stock #052-003-01291-0
NTIS order #PB92-216142
| |||
| Cystic Fibrosis and DNA Tests: Implications of Carrier Screening OTA-BA-532 | | |
| |||
| | |
| Full Report ~6731K | ||
 | ||
| Front Matter ~51K | ||
| Table of Contents ~4K | ||
Chapters | ||
| 1: Summary, Policy Issues, and Congressional Options ~1176K | ||
| 2: Introduction ~358K | ||
| 3: Medical Aspects ~328K | ||
| 4: The State-of-the-Art in Genetics ~875K | ||
| 5: Quality Assurance ~636K | ||
| 6: Education and Counseling ~467K | ||
| 7: Financing ~421K | ||
| 8: Discrimination Issues ~511K | ||
| 9: Costs and Cost-Effectiveness ~192K | ||
| 10: Cystic Fibrosis Carrier Screening in the United Kingdom ~240K | ||
Appendixes | ||
| A: Epidemiology of Mutations for Cystic Fibrosis ~378K | ||
| B: Case Studies of Other Carrier Screening Programs ~599K | ||
| C: Acknowledgments ~20K | ||
| D: List of Contractor Documents ~4K | ||
| E: List of Workshops and Participants ~8K | ||
| F: Acronyms and Glossary ~54K | ||
| Index ~559K | ||
 | ||